Jaguar8 commented on a stock · Nov 25, 2024 22:00

NEWS

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) announced significant developments, including a Phase 3 accelerated approval registration trial for IFx-2.0 in first-line treatment of Merkel Cell Carcinoma, planned for first half of 2025.

The company entered a non-binding letter of intent to acquire Kineta's KVA12123, a Phase 2 ready VISTA inhibiting antibody.

TuHURA is advancing IFx-3.0, a tumor-targeted mRNA innate immune response agonist, and developing early discovery programs for bi-specific antibody drug conjugates.

The company secured $31 million in financing through a merger with Kintara, funding operations into late 2025, and raised an additional $5 million for the potential Kineta acquisition.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

11K Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8192

Followers

Following

93K

Visitors